The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients
Authors:
- Akemi HaraAHAkemi Hara
- Shun WatanabeSWShun Watanabe
- Toyoaki SawanoTSToyoaki Sawano
- Yuki SonodaYSYuki Sonoda
- Hiroaki SaitoHSHiroaki Saito
- Akihiko OzakiAOAkihiko Ozaki
- Masatoshi WakuiMWMasatoshi Wakui
- Tianchen ZhaoTZTianchen Zhao
- Chika YamamotoCYChika Yamamoto
- Yurie KobashiYKYurie Kobashi
- Toshiki AbeTAToshiki Abe
- Takeshi KawamuraTKTakeshi Kawamura
Open Access
Abstract
Background: Hemodialysis patients, due to impaired kidney function and compromised immune responses, face increased risks from SARS-CoV-2. Anti-nucleocapsid IgG (anti-IgG N) antibodies are a commonly used marker to assess prior infection in the general population; however, their efficacy for hemodialysis patients remains unclear. Methods: A retrospective study of 361 hemodialysis patients evaluated anti-IgG N antibodies for detecting prior SARS-CoV-2 infection. Antibody levels were measured using a chemiluminescence immunoassay (CLIA) over the four time points. Boxplots illustrated antibody distribution across sampling stages and infection status. Logistic regression and receiver operating characteristic (ROC) curve analysis determined diagnostic accuracy, sensitivity, specificity, and optimal cutoff values. Results: Among the 361 hemodialysis patients, 36 (10.0%) had SARS-CoV-2 infection. Sex distribution showed a trend toward significance (p = 0.05). Boxplot analysis showed that anti-IgG N levels remained low in non-infected patients but increased in infected patients, peaking at the third sampling. Anti-IgG N demonstrated high diagnostic accuracy (AUC: 0.973–0.865) but declined over time (p = 0.00525). The optimal cutoff at C1 was 0.01 AU/mL (sensitivity 1.00, specificity 0.94). Adjusted models had lower predictive value. Conclusions: Anti-IgG N antibodies showed high diagnostic accuracy for detecting prior SARS-CoV-2 infection in hemodialysis patients, though performance declined over time. These findings highlight the need for tailored diagnostic strategies in this vulnerable population.Keywords
Funding Information
- Japan Agency for Medical Research and Development (AMED) (JP21nf0101638, 23H00503)
- Moderna, Inc. (JP21nf0101638, 23H00503)
- JSPS KAKENHI (JP21nf0101638, 23H00503)
- Medical and Biological Laboratories Co., Ltd. (JP21nf0101638, 23H00503)
- Shenzhen YHLO Biotech Co., Ltd. (JP21nf0101638, 23H00503)
- Kowa Co. (JP21nf0101638, 23H00503)
- Research Center for Advanced Science and Technology at the University of Tokyo (JP21nf0101638, 23H00503)
This publication has 23 references indexed in Scilit:
- Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccineVaccine, 2022
- Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccineThe Lancet Regional Health - Europe, 2021
- Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patientsThe Lancet, 2021
- Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune statusClinical Kidney Journal, 2021
- COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis ProviderAmerican Journal of Kidney Diseases, 2021
- Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across EuropeKidney International, 2020
- Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19New England Journal of Medicine, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Minimizing the risk of COVID-19 among patients on dialysisNature Reviews Nephrology, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020